PI Industries Limited (PIIND) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

PI Industries enters its Q1 FY27 results following a year of global destocking and volume pressures that led to a 16% revenue decline in FY26. Investors will be looking for signs of a recovery in the CSM export segment and the impact of the government's temporary zero-duty window on critical chemical imports.

PI Industries Limited Q1 Results Date and Time

The company has scheduled a board meeting for August 11, 2026, to consider the unaudited financial results for the quarter ended June 30, 2026.

An earnings conference call is scheduled for August 12, 2026, at 12:00 noon IST.

What to expect from PI Industries Limited's Q1 FY27 results

PI Industries is positioned for a potential revenue inflection in Q1, marking a shift from the four-quarter decline observed through FY26. Management has guided for positive revenue growth for FY27, supported by the stabilization of the global AgChem destocking cycle and a seasonally strong Q1 base of Rs. 1,900.5 Cr in the previous year. The company's cost structure in Q1 benefited from the government's zero-duty window on over 40 critical chemical intermediates, which remained effective through June 30, 2026. Additionally, the depreciation of the rupee past the Rs. 95/USD level serves as a tailwind for export realizations, potentially aiding a sequential recovery in EBITDA margins from the 22% level recorded in Q4 FY26. The upcoming call will likely focus on whether the zero-duty benefit improved margins or was passed through to customers, alongside updates on the pharma segment's progress toward sustained EBITDA positivity.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against management's stated FY27 targets and long-term goals.

• FY27 Revenue Growth — positive growth expected — Q1 YoY performance vs FY26 decline
• EBITDA Margin — 25–27% long-term target — Q1 trajectory vs Q4 22% print
• Pharma CDMO Revenue — Rs. 500–600 Cr in 2–3 years — FY26 base of Rs. 400 Cr
• FY27 Capex — Rs. 700–800 Cr — Q1 actual spend vs annual plan

Operating metric trajectory: Key indicators of demand and operational efficiency.

• CSM Order Book — $1.0–1.2 Bn as of Q4 FY26 — directional change in pipeline
• Working Capital — 139 days in Q3 FY26 — progress toward normalization
• Pharma Segment — EBITDA positivity threshold of Rs. 400–500 Cr topline

Risks and headwinds to monitor: Management-flagged risks impacting current quarter performance.

• Patent risk for largest CSM molecule — status of gradual vs cliff decline disclosure
• Biologicals segment — impact of regulatory disruptions in India
• PIHS Provision — sufficiency of Rs. 110 Cr provision booked in Q4 FY26